PAP
CNTB

Persistent Asset Partners’s Connect Biopharma Holdings CNTB Stock Holding History

Persistent Asset Partners’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
50,747
+23,973
+90% +$62.5K 0.05% 225
2025
Q4 		$75.5K Buy
+26,774
New +$57.1K 0.03% 278

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Persistent Asset Partners's CNTB Position: Q1 2026 in Review

Persistent Asset Partners increased its Connect Biopharma Holdings (CNTB) stake by 90% in Q1 2026, buying an estimated $62.5K and bringing the position to 50,747 shares worth $133K. The position accounts for 0.05% of the portfolio, ranked #225.

Persistent Asset Partners first reported a position in CNTB in Q4 2025 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

  • Persistent Asset Partners held 50,747 shares of Connect Biopharma Holdings worth $133K as of Q1 2026.
  • Persistent Asset Partners bought 23,973 Connect Biopharma Holdings shares in Q1 2026, an estimated $62.5K.
  • Connect Biopharma Holdings made up 0.05% of Persistent Asset Partners's portfolio in Q1 2026, its #225 holding.
  • Persistent Asset Partners first reported a position in Connect Biopharma Holdings in Q4 2025 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.